Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Montelukast in Nasal Recruitment of CD49d+ Neutrophils
NCT03039101Completed
- Start
- Sep 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in allergic rhinitis (AR) comparing Montelukast Sequence with Placebo Sequence (2 arms). Primary endpoint: Change in frequency of CD49d+ neutrophils in nasal lavage at 1 month. Started Sep 2017; status: completed.
02
Drugs
montelukast
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03039101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03039101.